One for the Price of Two...Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors?

Trends in Pharmacological Sciences

Volumn 37, Issue 5, 2016, Pages 353-363

  Glass, Michelle ^a   Govindpani, Karan ^a   Furkert, Daniel P ^a   Hurst, Dow P ^b   Reggio, Patricia H ^b   Flanagan, Jack U ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

dual acting ligands; G protein coupled receptors; heteromer; oligomers

Indexed keywords

AM 841; BETA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DELTA OPIATE RECEPTOR; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; MU OPIATE RECEPTOR; OREXIN 1 RECEPTOR; RHODOPSIN; RIMONABANT; SALMETEROL; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR; LIGAND;

BINDING AFFINITY; BINDING SITE; EXTRACELLULAR SPACE; HYDROPHILICITY; IN VIVO STUDY; LIPID BILAYER; LIPOPHILICITY; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; CHEMISTRY; METABOLISM; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; PROTEIN MULTIMERIZATION;

CANNABINOID RECEPTOR AGONISTS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN MULTIMERIZATION; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID;

EID: 84964381114     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.01.010     Document Type: Review

References (43)

1. J. Shonberg, and et al. Design strategies for bivalent ligands targeting GPCRs ChemMedChem 6 2011 963 974
2. J. Fernandez-Ruiz, and et al. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications Neurotherapeutics 12 2015 793 806
3. R.P. Picone, and D.A. Kendall Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation Mol. Endocrinol. 29 2015 801 813
4. M. Jorg, and et al. Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease J. Med. Chem. 58 2015 718 738
5. J. Kuhhorn, and et al. Development of a bivalent dopamine D(2) receptor agonist J. Med. Chem. 54 2011 7911 7919
6. J. Vagner, and et al. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and δ-opioid receptors Angew. Chem. Int. Ed. Engl. 47 2008 1685 1688
7. P.S. Portoghese From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes J. Med. Chem. 44 2001 2259 2269
8. P.S. Portoghese, and A.E. Takemori Different receptor sites mediate opioid agonism and antagonism J. Med. Chem. 26 1983 1341 1343
9. A. Szczuka, and et al. Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol Br. J. Pharmacol. 158 2009 183 194
10. J. Wager-Miller, and et al. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example Chem. Phys. Lipids 121 2002 83 89
11. J. Ellis, and et al. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function J. Biol. Chem. 281 2006 38812 38824
12. A.N.M. Schoffelmeer, and et al. Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core Neuropharmacology 51 2006 773 781
13. C.S. Kearn, and et al. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 67 2005 1697 1704
14. Y. Zhang, and et al. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 53 2010 7048 7060
15. 1 receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR 141716) J. Med. Chem. 45 2002 2708 2719
16. B.F. Thomas, and et al. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide (SR 141716) with unique binding selectivities and pharmacological activities Bioorg. Med. Chem. 13 2005 5463 5474
17. B. Dyck, and et al. Potent imidazole and triazole CB1 receptor antagonists related to SR 141716 Bioorg. Med. Chem. Lett. 14 2004 1151 1154
18. P.S. Portoghese, and et al. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem. 29 1986 1855 1861
19. D.P. Hurst, and et al. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor J. Biol. Chem. 285 2010 17954 17964
20. G. Huang, and et al. Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure Bioorg. Med. Chem. Lett. 24 2014 4209 4214
21. C. Fernández-Fernández, and et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results Drug Design Dev. Ther. 8 2014 263 277
22. D. Hurst, and et al. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction J. Med. Chem. 49 2006 5969 5987
23. 1 transmembrane helix 7 Mol. Pharmacol. 71 2007 1512 1524
24. J. Barnett-Norris, and et al. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation Int. J. Quantum Chem. 88 2002 76 86
25. 1 receptor activation J. Biol. Chem. 279 2004 48024 48037
26. C. Fernández-Fernández, and et al. Description of a bivalent cannabinoid ligand with hypophagic properties Arch. Pharm. (Weinheim) 346 2013 171 179
27. 1) receptors are potent analgesics devoid of tolerance J. Med. Chem. 56 2013 5505 5513
28. D.A. Perrey, and et al. Toward the development of bivalent ligand probes of cannabinoid CB1 and orexin OX1 receptor heterodimers ACS Med. Chem. Lett. 5 2014 634 638
29. J.M. Johnston, and et al. Making structural sense of dimerization interfaces of delta opioid receptor homodimers Biochemistry 50 2011 1682 1690
30. W. Guo, and et al. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer J. Biol. Chem. 278 2003 4385 4388
31. H. Zheng, and et al. Palmitoylation and membrane cholesterol stabilize μ-opioid receptor homodimerization and G protein coupling BMC Cell Biol. 13 2012 1 18
32. B. Wu, and et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
33. 2H-NMR Biochim. Biophys. Acta 986 1989 141 145
34. X.Q. Xie, and et al. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling J. Med. Chem. 41 1998 167 174
35. R. Mechoulam, and et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
36. T. Sugiura, and et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 215 1995 89 97
37. W.A. Devane, and et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
38. V. Di Marzo Endocannabinoids: synthesis and degradation Rev. Physiol. Biochem. Pharmacol. 160 2008 1 24
39. M.A. Hanson, and et al. Crystal structure of a lipid G protein-coupled receptor Science 335 2012 851 855
40. A. Srivastava, and et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature 513 2014 124 127
41. R.P. Picone, and et al. (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor Mol. Pharmacol. 68 2005 1623 1635
42. Y. Pei, and et al. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation Chem. Biol. 15 2008 1207 1219
43. J.E. Chrencik, and et al. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1 Cell 161 2015 1633 1643